This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pfizer's Drug Problem: Lipitor

Pfizer faces a daunting task because generic Zocor is now sold by 11 companies, and that means intense price competition. Customers of course find the idea of paying less hard to resist.

A recent Bear Stearns report says the annual wholesale acquisition cost for generic Zocor is $20 to $58 depending on the dose. The annual cost for Lipitor is $874 to $1,246. The wholesale acquisition cost is the list price charged by drugmakers to wholesalers or direct purchasers, excluding discounts or rebates. Meanwhile, the annual cost is $913 for Zetia, $983 for Vytorin and $945 for Crestor.

Pfizer has two ways to defend Lipitor. It can cut prices and offer rebates to protect its prescription-market share, or it can raise prices to prop up revenue as prescriptions slip.

For now, it's doing both. In January, it raised Lipitor's price by 5%, and Pfizer attributed its first-quarter sales gain from the product to the price hike.

On May 30, it also signed a deal with Express Scripts, (ESRX) to offer rebates on Lipitor. In return, the giant pharmacy benefits management firm placed Lipitor back on its list of preferred brand-name drugs, meaning its customers will pay less out of pocket.

Managed care firms usually have three tiers of products. Generics, which require the lowest copayments, are in Tier 1. Preferred brand-name drugs are in Tier 2, and nonpreferred drugs are in Tier 3 and carry the highest copayments.

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs